Business Description
Solvonis Therapeutics is a London-based drug development company focused on creating new treatments for addiction and mental health conditions. Its most advanced drug, SVN-001, is currently in late-stage clinical trials for severe alcohol use disorder, while a second drug, SVN-002, has already passed early safety testing for a similar purpose. The company is also working on an early-stage treatment for post-traumatic stress disorder. Founded in 2017 and previously known as Graft Polymer (UK) Plc, the company adopted its current name at the start of 2025.
